44.

Mactal-Haaf C, Hoffman M, and Kuchta A, "Use of Anti-infective Agents During Lactation, Part 3: Antivirals,
Antifungals, and Urinary Antiseptics," J Hum Lact, 2001, 17(2):160-6. [PubMed 11847833]

45. Martinez-Pajares JD, Martinez-Ferriz MC, Moreno-Perez D, et al, "Management of Obstructive Renal Failure Caused
by Bilateral Renal Aspergilloma in an Immunocompetent Newborn," J Med Microbiol, 2010, 59(Pt 3):367-9.
[PubMed 19910484]

46. Mohr J, Johnson M, Cooper T, et al, “Current Options in Antifungal Pharmacotherapy,” Pharmacotherapy, 2008,
28(5):614-45. [PubMed 18447660]

47. Murphy K, Bradley J, and James HE, "The Treatment of Candida albicans Shunt Infections," Childs Nerv Syst, 2000,
16(1):4-7. [PubMed 10672422]

48. Nesbit SA, Ketz KE, McClain BW, et al. Comparison of two concentrations of amphotericin B bladder irrigation in
the treatment of funguria in patients with indwelling urinary catheters. Am J Health Syst Pharm. 1999;56(9):872-
875. [PubMed 10344610]

49. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure
and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and
Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes
Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart
Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69.
[PubMed 27400984]

50. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016
update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933.
[PubMed 26679628]10.1093/cid/civ933

51. Patel R, “Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,” Mayo Clin Proc, 1998,
73(12):1205-25. [PubMed 9868423]

52. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of
aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html.
Accessed August 8, 2016.27365388

53. Peleg AY and Woods ML, "Continuous and 4 h Infusion of Amphotericin B: A Comparative Study Involving High-
Risk Haematology Patients," J Antimicrob Chemother, 2004, 54(4):803-8. [PubMed 15308606]

54. Perfect JR, Dismukes WE, Dromer F, et al, “Clinical Practice Guidelines for the Management of Cryptococcal
Disease: 2010 Update by the Infectious Diseases Society of America,” Clin Infect Dis, 2010, 50(3):291-322. [PubMed
20047480]

55. Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother.
2015;70(1):14-22. doi: 10.1093/jac/dku355. [PubMed 25204341]10.1093/jac/dku355

56. Raaijmakers R, Schröder C, Monnens L, et al, "Fungal Peritonitis in Children on Peritoneal Dialysis," Pediatr
Nephrol, 2007, 22(2):288-93. [PubMed 17111161]

57. Rex JH, Bennett JE, Sugar AM, “A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment
of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,” N Engl J
 Med, 1994, 331(20):1325-30. [PubMed 7935701]

58. Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new
antifungal agents. Clin Infect Dis. 2011;52(5):648-653. doi: 10.1093/cid/ciq204. [PubMed 21239843]

59. Ritterband D, Kelly J, McNamara T, Kresloff M, Koplin R, Seedor J. Delayed-onset multifocal polymicrobial keratitis
after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28(5):898-899. [PubMed 11978476]

60. Slain D, “Lipid-Based Amphotericin B for the Treatment of Fungal Infections,” Pharmacotherapy, 1999, 19(3):306-
23. [PubMed 10221369]

61. Stevens DA and Shatsky SA, "Intrathecal Amphotericin in the Management of Coccidioidal Meningitis," Semin
Respir Infect, 2001, 16(4):263-9. [PubMed 11740828]

62. Tamcelik N, Ozdamar A, Kizilkaya M, Devranoglu K, Ustundag C, Demirkesen C. Fungal keratitis after
nonpenetrating glaucoma surgery. Cornea. 2002;21(5):532-534. [PubMed 12072733]

63. The Ad Hoc Advisory Panel on Peritonitis Management. “Continuous Ambulatory Peritoneal Dialysis (CAPD)
Peritonitis Treatment Recommendations: 1989 Update,” Perit Dial Int, 1989, 9(4):247-56. [PubMed 2488376]

64. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for
healthcare-associated ventriculitis and meningitis [published online February 14, 2017]. Clin Infect Dis. doi:
10.1093/cid/ciw861. [PubMed 28203777]

65. Turcu R, Patterson MJ, and Omar S, "Influence of Sodium Intake on Amphotericin B-Induced Nephrotoxicity
Among Extremely Premature Infants," Pediatr Nephrol, 2009, 24(3):497-505. [PubMed 19082636]

66. Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line
therapy - is there a 'right' choice? Curr Opin Infect Dis. 2011;24(2):163-171. [PubMed 21301335]

67. US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected
Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-
infected children: recommendations from the National Institutes of Health, Centers for Disease Control and
Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious
Diseases Society, and the American Academy of Pediatrics.
https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Accessed September 29, 2017.

68. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents
with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with
HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and
the HIV Medicine Association of the Infectious Diseases Society of America.
http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed April 27, 2020.

69. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-
related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int.
2012;32 Suppl 2:S32-86. [PubMed 22851742]

70. Warady BA, Bashir M, Donaldson LA. Fungal peritonitis in children receiving peritoneal dialysis: a report of the
NAPRTCS. Kidney Int. 2000a;58(1):384-389. [PubMed 10886585]

71. Warady BA, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric
patients receiving peritoneal dialysis. Perit Dial Int, 2000b;20(6):610-624. [PubMed 11216549]
 72. Wasmann RE, Smit C, van Dongen EPH, et al. Fixed dosing of liposomal amphotericin B in morbidly obese
individuals. Clin Infect Dis. 2020;70(10):2213-2215. doi:10.1093/cid/ciz885 [PubMed 31588493]

73. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with
histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807-825.
[PubMed 17806045]

74. Wiest DB, Maish WA, Garner SS, el-Chaar GM. Stability of amphotericin B in four concentrations of dextrose
injection. Am J Hosp Pharm. 1991;48(11):2430-2433. [PubMed 1746578]

75. Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory
keratomycosis and endophthalmitis. Cornea. 2007;26(4):398-402. [PubMed 17457185]

Topic 8701 Version 212.0